Decibel Therapeutics Inc is a biotechnology business based in the US. Decibel Therapeutics shares (DBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Decibel Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Decibel Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DBTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Decibel Therapeutics stock price (NASDAQ: DBTX)Use our graph to track the performance of DBTX stocks over time.
Decibel Therapeutics shares at a glance
|Latest market close||$7.47|
|52-week range||$6.18 - $24.39|
|50-day moving average||$8.00|
|200-day moving average||$8.21|
|Wall St. target price||$24.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.26|
Buy Decibel Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Decibel Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Decibel Therapeutics price performance over time
|1 week (2021-10-14)||-0.53%|
|1 month (2021-09-21)||-10.86%|
|3 months (2021-07-21)||3.89%|
|6 months (2021-04-21)||-25.67%|
|1 year (2020-10-17)||N/A|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
Decibel Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-40.97%|
|Return on equity TTM||-145.27%|
|Market capitalisation||$188.2 million|
TTM: trailing 12 months
Shorting Decibel Therapeutics shares
There are currently 267,384 Decibel Therapeutics shares held short by investors – that's known as Decibel Therapeutics's "short interest". This figure is 44.4% down from 481,088 last month.
There are a few different ways that this level of interest in shorting Decibel Therapeutics shares can be evaluated.
Decibel Therapeutics's "short interest ratio" (SIR)
Decibel Therapeutics's "short interest ratio" (SIR) is the quantity of Decibel Therapeutics shares currently shorted divided by the average quantity of Decibel Therapeutics shares traded daily (recently around 49978.317757009). Decibel Therapeutics's SIR currently stands at 5.35. In other words for every 100,000 Decibel Therapeutics shares traded daily on the market, roughly 5350 shares are currently held short.
To gain some more context, you can compare Decibel Therapeutics's short interest ratio against those of similar companies.
However Decibel Therapeutics's short interest can also be evaluated against the total number of Decibel Therapeutics shares, or, against the total number of tradable Decibel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Decibel Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Decibel Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.024% of the tradable shares (for every 100,000 tradable Decibel Therapeutics shares, roughly 24 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Decibel Therapeutics.
Find out more about how you can short Decibel Therapeutics stock.
Decibel Therapeutics share dividends
We're not expecting Decibel Therapeutics to pay a dividend over the next 12 months.
Decibel Therapeutics overview
Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc.
Decibel Therapeutics in the news
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
Decibel Therapeutics : to Present at the Jefferies Gene Therapy/Editing Summit
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
Frequently asked questionsWhat percentage of Decibel Therapeutics is owned by insiders or institutions?
Currently 20.591% of Decibel Therapeutics shares are held by insiders and 72.155% by institutions. How many people work for Decibel Therapeutics?
Latest data suggests 40 work at Decibel Therapeutics. When does the fiscal year end for Decibel Therapeutics?
Decibel Therapeutics's fiscal year ends in December. Where is Decibel Therapeutics based?
Decibel Therapeutics's address is: 1325 Boylston Street, Boston, MA, United States, 02215 What is Decibel Therapeutics's ISIN number?
Decibel Therapeutics's international securities identification number is: US24343R1068
More guides on Finder
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Ask an Expert